Welcome to our website

Help us direct you to the right information by selecting one of the following options:

I'm a Healthcare Professional

The content on this website is intended for U.S. Healthcare Professionals. By entering this website, you confirm you are a U.S. Healthcare Professional

I am a Healthcare Professional

I'm NOT a Healthcare Professional

The content on this website is intended for Healthcare Professionals only.

For more information about a prescription treatment option, click below

I am NOT a Healthcare Professional

Disclaimer:

You are now leaving this website and are going to a website that is not operated by EMD Serono. We are not responsible for the content or availability of linked sites.

If you have any questions or concerns about the products and services offered on linked third-party websites, please contact the third party directly.

Cancel

Cladribine Tablets and COVID-19

• EMD Serono is continuing to conduct safety surveillance to identify and evaluate drug safety risks

• As of 7 September 2020, 85 suspected cases of COVID-19 occurring in patients treated with Cladribine Tablets have been reported to the Merck KGaA, Darmstadt, Germany safety database

• Of these 85 cases, 38 cases are positively confirmed COVID-19

image-1

aIncludes 5 patients with negative PCR test

Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with Cladribine Tablets

Jack D, Nolting A, Galazka A

Mult Scler Relat Disord 2020;102469

https://doi.org/10.1016/j.msard.2020.102469

DJ and AN are employees of Merck KGaA, Darmstadt, Germany. AG is an employee of Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany.

 

• Letter to the editor reporting outcomes of patients receiving Cladribine Tablets who have contracted COVID-19 and have been reported to the Merck KGaA, Darmstadt, Germany Global Patient Safety Database (data cut-off 29 June 2020)